07:44 AM EDT, 04/22/2024 (MT Newswires) -- XORTX Therapeutics Inc. ( XRTX ) , a pharmaceutical company developing therapies to treat progressive kidney disease, on Monday announced a research paper showing for the first time that prolonged increased serum uric acid (SUA) can significantly increase cyst growth and kidney size in ADPKD in mice or rat models of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A fundamental new discovery from this study was also that over expression of xanthine oxidase (XO) in kidney tissue was present, suggesting a possible role of XO in disease progression, a statement reports.

The paper has been accepted for publication in the peer-reviewed American Journal of Physiology-Renal Physiology and published online April 19.